Monoclonal antibodies that target pathological assemblies of amyloid beta (abeta)

Abstract

Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods utilizing such antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.

1 - 3 . (canceled) 
     
     
         4 . A method for producing an oligomeric amyloid β1-42-selective antibody comprising
 (a) injecting oligomeric amyloid β1-42 into an animal to induce an immune response to the oligomeric amyloid β1-42; 
 (b) isolating antibodies that bind to oligomeric amyloid β1-42; 
 (c) selecting antibodies of (b) that do not bind to either monomeric amyloid β1-42, amyloid β1-40 or fibrillar amyloid β thereby producing an oligomeric amyloid β1-42-selective antibody.